Invention Grant
- Patent Title: Anti-BTN3A antibodies and their use in treating cancer or infectious disorders
-
Application No.: US18327127Application Date: 2023-06-01
-
Publication No.: US11945871B2Publication Date: 2024-04-02
- Inventor: Alemseged Truneh , Daniel Olive , Christine Pasero , Aude De Gassart
- Applicant: Imcheck Therapeutics SAS , INSERM (Institut National de la Santé et de la Recherche Médicale) , Université d'Aix Marseille , Institut Jean Paoli & Irene Calmette , Centre National de la Recherche Scientifique—CNRS
- Applicant Address: FR Marseilles
- Assignee: IMCHECK THERAPEUTICS SAS,INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE),UNIVERSITE AIX MARSEILLE,INSTITUT JEAN PAOLI & IRENE CALMETTE,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
- Current Assignee: IMCHECK THERAPEUTICS SAS,INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE),UNIVERSITE AIX MARSEILLE,INSTITUT JEAN PAOLI & IRENE CALMETTE,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
- Current Assignee Address: FR Marseilles; FR Paris; FR Marseilles; FR Marseilles; FR Paris
- Agency: WCF IP
- Priority: EP 306050 2018.08.01 EP 153992 2019.01.28
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K9/19 ; A61K38/20 ; A61K39/395 ; A61P35/00 ; A61K39/00
Abstract:
The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.
Public/Granted literature
- US20230322932A1 ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERS Public/Granted day:2023-10-12
Information query
